Evidence map›Paper›PMID 34309796›Full record

ReviewMolecular biotechnology2021

Alternatives to Conventional Antibiotic Therapy: Potential Therapeutic Strategies of Combating Antimicrobial-Resistance and Biofilm-Related Infections.

Qian Xu, Xuefeng Hu, Yunbing Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Montelukast treatsMicrobiology spectrum · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qian XuNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610065, Sichuan, People's Republic of China.
Xuefeng HuNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610065, Sichuan, People's Republic of China. hu_xf@qq.com.ORCID http://orcid.org/0000-0001-9683-3506
Yunbing WangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610065, Sichuan, People's Republic of China. yunbing.wang@scu.edu.cn.

Funding

Clinical Research Incubation Project No. 2019HXFH006National Natural Science Foundation of China 51903176Special Fund for Nursing Discipline Development No. HXHL19003
6 · The paper itself

Abstract

Antibiotics have been denoted as the orthodox therapeutic agents for fighting bacteria-related infections in clinical practices for decades. Nevertheless, overuse of antibiotics has led to the upsurge of species with antimicrobial resistance (AMR) or multi-drug resistance. Bacteria can also grow into the biofilm, which accounts for at least two-thirds of infections. Distinct gene expression and self-produced heterogeneous hydrated extracellular polymeric substance matrix architecture of biofilm contribute to their tolerance and externally manifest as antibiotic resistance. In this review, the difficulties in combating biofilm formation and AMR are introduced, and novel alternatives to antibiotics such as metal nanoparticles and quaternary ammonium compounds, chitosan and its derivatives, antimicrobial peptides, stimuli-responsive materials, phage therapy and other therapeutic strategies, from compounds to hydrogel, from inorganic to biological, are discussed. We expect to provide useful information for the readers who are seeking for solutions to the problem of AMR and biofilm-related infections.

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesBacteriaBacterial InfectionsBiofilmsDrug Resistance, BacterialExtracellular Polymeric Substance MatrixHumansMetal NanoparticlesPhage TherapyQuaternary Ammonium CompoundsAnti-Bacterial AgentsAntimicrobial PeptidesQuaternary Ammonium CompoundsAMRAntibioticsBacteriaBiofilmInfectionTherapeutic strategies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.